National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Anxiety Disorder (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 08/20/2008



Purpose of This PDQ Summary






Overview






Description and Etiology






Screening and Assessment






Treatment






Posttreatment Considerations






Get More Information From NCI






Changes to This Summary (08/20/2008)






Questions or Comments About This Summary






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Posttreatment Considerations

After treatment, patients are confronted with a number of issues related to cancer survivorship. Typical issues involve fears about repeated medical follow-up and diagnostic tests. Fear of recurrence is also an ongoing concern that waxes and wanes over time. A number of specific issues can be a source of anxiety. Fears related to returning to work, such as discussing one’s treatment with employees, insurance-related problems, and concerns about discrimination, can cause distress. Fear of screening, follow-up, and risk of second malignancies are ongoing physical threats that are accompanied by anxiety for certain subgroups of patients. Body-image changes, sexual dysfunction, and reproductive issues can also cause anxiety. Posttraumatic stress disorder has been diagnosed in about 3% to 5% of patients who survive cancer and its effects, depending on site and intensity of treatment. In a study of women who were taking tamoxifen for breast cancer, trait anxiety was associated with a higher dropout rate from tamoxifen therapy due to a higher incidence of adverse physiological side effects.[1] (Refer to the PDQ summary on Post-Traumatic Stress Disorder for more information.) Survivorship programs and resources, including group and individual counseling, can help facilitate adjustment and can address specific concerns. (Refer to the PDQ summary on Transitional Care Planning for more information.)

References

  1. Cameron LD, Leventhal H, Love RR, et al.: Trait anxiety and tamoxifen effects on bone mineral density and sex hormone- binding globulin. Psychosom Med 64 (4): 612-20, 2002 Jul-Aug.  [PUBMED Abstract]

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov